Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102) (International Journal of Clinical Oncology, (2016), 21, 4, (705-712), 10.1007/s10147-015-0943-z);S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

International Journal of Clinical Oncology

Volumn 21, Issue 4, 2016, Pages 705-712

  Miyamoto, Yuji ^a   Tsuji, Akihito ^b   Tanioka, Hiroaki ^c   Maekawa, Soichiro ^d   Kawanaka, Hirofumi ^e,f   Kitazono, Masaki ^g   Oki, Eiji ^h   Emi, Yasunori ⁱ   Murakami, Hidetsugu ^j   Ogata, Yutaka ^k   Saeki, Hiroshi ^g   Shimokawa, Mototsugu ^l   Natsugoe, Shoji ^m   Akagi, Yoshito ^j   Baba, Hideo ^a   Maehara, Yoshihiko ^h  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c Japan Labour Health and Welfare Organization   (Japan)

^d Munakata Medical Association Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^f Clinical Research Institute and Department of Surgery   (Japan)

^g Gastroenterological Surgery   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^j KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m KAGOSHIMA UNIVERSITY   (Japan)

more..

Author keywords

Bevacizumab; Chemotherapy; Colorectal cancer; Irinotecan; S 1

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; JAPAN; LEUKEMIA; MALAISE; MALE; METASTATIC COLORECTAL CANCER; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; TEGAFUR; TREATMENT OUTCOME;

EID: 84953407424     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-017-1212-0     Document Type: Erratum

References (30)

1. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004–4009
2. Shirasaka T, Nakano K, Takechi T et al (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602–2606
3. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drug 7:548–557
4. Miyamoto Y, Sakamoto Y, Yoshida N et al (2014) Efficacy of S-1 in colorectal cancer. Expert Opin Pharmacother 15:1761–1770
5. Goto A, Yamada Y, Yasui H et al (2006) Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17:968–973
6. Yoshioka T, Kato S, Gamoh M et al (2009) Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer 101:1972–1977
7. Komatsu Y, Yuki S, Sogabe S et al (2012) Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 51:867–872
8. Yamada Y, Yamaguchi T, Matsumoto H et al (2012) Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drug 30:1690–1696
9. Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860
10. Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479–2516
11. Wagner AD, Arnold D, Grothey AA et al (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. doi:10.1002/14651858
12. Strickler JH, Hurwitz HI (2014) Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 16:363
13. Welch S, Spithoff K, Rumble RB et al (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21:1152–1162
14. Baba H, Watanabe M, Okabe H et al (2012) Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br J Cancer 107:1950–1955
15. Komatsu Y, Yuki S, Sogabe S et al (2011) Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80:70–75
16. Shiozawa M, Akaike M, Sugano N et al (2010) A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 66:987–992
17. Oh SY, Ju YT, Choi SK et al (2011) Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. Invest New Drug 29:1050–1056
18. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914
19. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786
20. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37
21. Suenaga M, Nishina T, Mizunuma N et al (2015) Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer 15:176
22. Tsutsumi S, Ishibashi K, Uchida N et al (2012) Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study. Oncology 83:151–157
23. Bendell JC, Tournigand C, Swieboda-Sadlej A et al (2013) Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin Colorectal Cancer 12:239–247
24. Nakayama G, Uehara K, Ishigure K et al (2012) The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol 70:575–581
25. Iwamoto S, Takahashi T, Tamagawa H et al (2015) FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 26:1427–1433
26. Suenaga M, Mizunuma N, Matsusaka S et al (2015) A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther 9:1653–1662
27. Kubicka S, Greil R, André T et al (2014) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: outcomes according to KRAS status and first-line CT backbone in the ML18147 study. J Clin Oncol 32(suppl 3):S520
28. Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508
29. Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506
30. Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713